• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Study Finds Pandemic Mitigation Efforts Impacted Trial Completion Rates

Study Finds Pandemic Mitigation Efforts Impacted Trial Completion Rates

April 12, 2021

A new study finds that trials sponsored by the pharma industry fared better during the pandemic and were more likely to complete enrollment compared to trials sponsored by academia, hospitals and medical centers.

Pandemic mitigation efforts, such as social distancing and lockdowns, caused global trial completion rates to decline by 13 percent to 23 percent, depending on geographic location and who sponsored the trial, researchers from the Pennsylvania State College of Medicine found.

The researchers analyzed more than 117,000 clinical trials worldwide and also broke out trials conducted in the U.S., Europe and Asia. They compared the number of clinical trials submitted and completed between April and October in both 2019 and 2020, using data from the ClinicalTrials.gov database. To more accurately assess the impact of the pandemic, researchers analyzed the 2020 dataset both with and without data from trials related to COVID-19.

The study found a slight increase in the overall number of clinical trial submissions between April and October of 2020 compared to 2019, but with COVID-19 related trials removed, there was a 9.7 percent decrease in the number of submitted trials. Globally, there was a 13.3 percent decline in the number of clinical trials completed in 2020 with COVID-19 studies included, but that figure grows to a 16.7 percent decline without those studies. In the U.S., a 17 percent decline in completed trials occurred in 2020 with COVID-19 studies included; excluded, it was a 19.1 percent decline.

Read the report here: https://bit.ly/3wA8O48.

COVID-19
  • Related Directories

    Olumiant (baricitinib)

    Veklury (remdesivir)

    Comirnaty (COVID-19 Vaccine, mRNA)

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing